Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment.
Grundman M, Jack CR Jr, Petersen RC, Kim HT, Taylor C, Datvian M, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Darvesh S, Yaffe K, Kaye J, Ferris SH, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study. Grundman M, et al. J Mol Neurosci. 2003;20(3):241-8. doi: 10.1385/jmn:20:3:241. J Mol Neurosci. 2003. PMID: 14501003 Clinical Trial.
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ; Alzheimer's Disease Cooperative Study. Grundman M, et al. Among authors: van dyck ch. Arch Neurol. 2004 Jan;61(1):59-66. doi: 10.1001/archneur.61.1.59. Arch Neurol. 2004. PMID: 14732621 Clinical Trial.
Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment.
Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study. Fleisher A, et al. Among authors: van dyck ch. Arch Neurol. 2005 Jun;62(6):953-7. doi: 10.1001/archneur.62.6.953. Arch Neurol. 2005. PMID: 15956166 Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative. Savage MJ, et al. J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778. J Alzheimers Dis. 2015. PMID: 25790831 Free PMC article.
393 results